Phage Therapy Market Size, Share & Revenue Outlook 2032

shivani Ghodake 07:20:19 06/18/2026

According to a newly published market research report by 24LifeSciences, global phage therapy market was valued at USD 40.3 million in 2024 and is projected to reach USD 133 million by 2031, growing at a compound annual growth rate (CAGR) of 19.1% during the forecast period.

Phage therapy utilizes bacteriophages, viruses that specifically target and destroy bacteria, as an alternative or complement to traditional antibiotics. These natural predators of bacteria offer a promising solution to the global antimicrobial resistance (AMR) crisis, particularly against multi-drug resistant (MDR) pathogens. The World Health Organization estimates that AMR causes 1.27 million deaths annually and contributes to nearly 5 million deaths, highlighting the urgent need for such alternative therapies. Market growth is driven by increasing antibiotic resistance across human and veterinary medicine, rising investments in phage research and development, and regulatory advancements facilitating clinical applications.

Download a Free Sample Report (PDF): https://www.24lifesciences.com/download-sample/3594/phage-therapy-market

Rising Antibiotic Resistance Crisis Fuels Market Growth

The increasing global prevalence of antimicrobial resistant infections is creating unprecedented demand for alternative treatments. With over 1.2 million deaths annually attributed to antibiotic resistance, healthcare systems are urgently seeking solutions that can combat these superbugs without contributing to further resistance development. The expanding number of difficult-to-treat infections in hospital settings has significantly increased demand for reliable therapeutic alternatives.

In addition, phage therapy's proven role in targeting specific bacterial pathogens ensures a targeted approach that preserves beneficial microbiome, unlike broad-spectrum antibiotics that disrupt natural flora.

Advancements in Personalized Medicine Enhance Treatment Efficacy

Technological advancements in phage characterization and matching have transformed the treatment approach by improving therapeutic precision and patient-specific targeting. These innovations have strengthened clinical acceptance and enabled specialized therapy centers to develop personalized treatment protocols, supporting broader market expansion.

Ongoing clinical research exploring novel therapeutic applications, including chronic infection management and biofilm disruption, is further opening new growth avenues for the phage therapy market.

Market Challenges: Regulatory Hurdles and Standardization Issues

Despite positive growth trends, the market faces notable challenges:

Complex regulatory pathways for biological therapeutics
Standardization difficulties in phage characterization and production
Limited clinical trial data compared to established pharmaceuticals
Manufacturing scalability challenges for personalized treatments

Additionally, reimbursement uncertainties and insurance coverage have created adoption barriers, particularly in cost-sensitive healthcare markets.

Get the Complete Report & Table of Contents: https://www.24lifesciences.com/phage-therapy-market-3594

North America Leads the Global Phage Therapy Market

The North American region, led by the United States, dominates the global phage therapy market, accounting for significant market share. This leadership is driven by:

Advanced healthcare infrastructure and research capabilities
High awareness and prevalence of antimicrobial resistance
Supportive regulatory frameworks for innovative therapies
Strong investment in biotechnology and pharmaceutical research

Europe and Asia-Pacific remain important developing markets, supported by growing research initiatives and increasing clinical acceptance.

Animal Health Segment Dominates Market by Application

By application, animal health represents the largest and most established segment due to the urgent need for antibiotic alternatives in veterinary medicine and livestock production. The less stringent regulatory pathway for veterinary applications has enabled faster adoption and commercialization of phage-based products.

Competitive Landscape: Emerging Market with Specialized Players

The global phage therapy market features a dynamic competitive landscape with specialized biotechnology companies and research institutions leading development efforts. The competitive environment is shaped by research capabilities, intellectual property, and clinical development expertise.

Key companies profiled in the report include:

NPO Microgen
Proteon Pharmaceuticals
Phagelux
Intralytix
Micreos
Eliava BioPreparations
Locus Biosciences, Inc.
and More

Get the Complete Report & Table of Contents:
https://www.24lifesciences.com/phage-therapy-market-3594

Market Opportunities: Expanding Applications and Technological Innovation

Significant growth opportunities exist in expanding applications beyond human medicine into veterinary health, food safety, and agricultural applications. Furthermore, the development of advanced phage engineering technologies and AI-assisted phage matching is expected to generate new intellectual property and expand clinical adoption.

Access the Full Report

Download a Free Sample Report (PDF):
https://www.24lifesciences.com/download-sample/3594/phage-therapy-market

Get the Complete Report & Table of Contents:
https://www.24lifesciences.com/phage-therapy-market-3594

About 24LifeSciences

24LifeSciences is a leading provider of market intelligence and strategic research reports across pharmaceuticals, biotechnology, medical devices, and healthcare technologies. Our reports are designed to support data-driven decision-making for manufacturers, healthcare providers, investors, consultants, and policy makers worldwide.